AzTrials
AzTrials

Kidney TransplantPDFNCT06724211

Preventing Delayed Graft Function in Kidney Transplant Patients

A study testing Treatment bundle of care in people with Kidney Transplant and Kidney Failure, run by University Health Network, Toronto at 2 sites in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The health and quality of life benefits of kidney transplantation are reduced by delayed graft function (DGF). There are a number of modifiable risk factors associated with DGF, such as intraoperative hypotension, the type of intravenous fluid used, glycemic control, and the restriction of blood transfusions. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Kidney Transplant, Kidney Failure, Kidney Injury
What is being tested?
Treatment bundle of care
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
2 sitesCanada
Study dates
15 Jan 2025to Apr 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ≥ 18 years
  • Patients undergoing kidney transplantation
  • Living and deceased donor recipients

Who cannot join

  • Multi-organ transplant
  • Pre-emptive KT
  • Arterial line not planned for surgery

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Stuart Dr. McCluskey, MD, PhD, FRCPC contact

416-988-6233

Stuart.McCluskey@uhn.ca

Canada2 sites
  • University Health Network

    Toronto, Ontario, M5G 2C4

    Stuart Dr. McCluskey, MD, PhD, FRCPC

    Ryan Dr. McGinn, MD, MSc, FRCPC

  • University Health Network

    Toronto, Ontario

    Stuart Dr. McCluskey, PhD, MD, FRCPC, 416-988-6233, stuart.mccluskey@uhn.ca

    Wilton Dr. van Klei, MD, PhD

Other trials in Canada

About this study

Official title: Preventing Delayed Graft Function in Kidney Transplant Patients: A Single-centre, Randomised, Feasibility Trial

The health and quality of life benefits of kidney transplantation are reduced by delayed graft function (DGF). There are a number of modifiable risk factors associated with DGF, such as intraoperative hypotension, the type of intravenous fluid used, glycemic control, and the restriction of blood transfusions. However, these factors have been assessed individually, and their collective effect on reducing the risk of DGF requires further investigation. We first propose a pilot RCT to establish the feasibility of a definitive RCT examining the impact of a treatment bundle of care on DGF.

This will be a single centre, double-blinded pilot RCT including 50 adults undergoing kidney transplantation. Patients will be randomized to either the experimental group, which will consist of a treatment bundle of care, or to the control group, which will consist of routine clinical care for kidney transplant patients. The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure > 75 mmHg, identify and treat blood glucose > 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) < 70 g/L).

The primary outcome of this pilot study is the recruitment rate. Recruitment rate will be defined as the number of patients who are approached to participate in the study and who are randomized to either the experimental or control group, as a percentage of the total number of eligible kidney transplant patients. The secondary outcomes are: 1) protocol adherence rate and 2) follow-up rate. Protocol success will be defined as a ≥90% compliance with at least 3 of the 4 treatment bundle components. Patient follow-up will end at 90-days after transplant and the target is to follow ≥90% of the patients until this time. DGF and acute rejection will not be assessed in the feasibility trial, and instead this data will be analyzed in the full trial.

Read the detailed description

Background: A number of perioperative factors can impact graft function after kidney transplant, such as hypotension, type of intravenous fluid used, red blood cell transfusions and glycemic control. For example, we recently found that intraoperative hypotension was associated with DGF-CRR following kidney transplant, with a threshold mean arterial blood pressure of 65 mmHg (manuscript submitted). Furthermore, the odds of DGF-CRR increased when the MAP was < 75 mmHg. A method to manage blood pressure during kidney transplant is administering intravenous fluids, either with crystalloids or blood. A recent multicenter, randomized controlled trial showed that plasmalyte, a balanced crystalloid fluid, reduces the incidence of DGF-D after DD- kidney transplant by 25% (i.e. 40% to 30%) compared to normal saline. In the kidney transplant population, blood transfusion was reported to be associated with reduced graft function, early graft loss, and reduced patient survival. As the vast majority of patients receiving blood transfusion receive only 1-2 units, many transfusion events likely could be avoided with better adherence to appropriate triggers, potentially leading to improved outcomes following kidney transplant. Finally, irrespective of a pre-transplant diabetes diagnosis, hyperglycemia (blood sugar > 9.0 mmol/L) in the post-anesthesia care unit is associated with an increased odds of DGF-D following kidney transplant. Therefore, glucose control (i.e. blood sugar < 9 mmol/L) may improve immediate graft function in this patient population.

Rationale: Preserving graft function following kidney transplant is critical to ensuring favourable outcomes. We propose to study the application of a modified version of the KDIGO guidelines for kidney transplant patients. This perioperative bundle of care includes maintenance of MAP >75 mmHg after kidney reperfusion, use of plasmalyte for fluid administration, reducing red blood cell transfusion and identifying and treating a blood sugar > 9 mmol/L. Although this care bundle shows promise for reducing the risk of DGF following transplant, this should first be investigated in a pilot, feasibility trial to ensure successful patient recruitment and adherence to the study protocol, prior to undergoing a full RCT.

Hypothesis: We hypothesize that the proposed perioperative bundle of care will be feasible to implement and improve postoperative outcomes for kidney transplant recipients.

Primary Objectives: The primary objective is to determine the feasibility of recruiting and randomizing kidney transplant recipients to an RCT evaluating the administration of a perioperative bundle of care. Recruitment rate will be defined as the number of patients who are approached to participate in the study and who are randomized to either the treatment or routine clinical care group, as a percentage of the total number of eligible transplant patients. In order to complete a full multicenter trial in a reasonable time period (2-3 years), the number needed to recruit per week is at least 1 patient, but we will aim to recruit 2 patients per week.

The secondary objective is to determine protocol adherence and follow-up rates. The aim is for ≥90% compliance with at least 3 of the 4 components of the perioperative bundle of care i.e. use of Plasmalyte for fluid management, maintenance of MAP > 75 mmHg from time of cross-clamp removal to 4-hours post KT, the initiation of an insulin infusion to maintain a serum blood sugar < 9 mmol/L and avoidance of RBC transfusion unless the Hb < 70 g/L or symptoms of oxygen insufficiency and Hb < 80 g/L. For this trial, patient follow-up will end at 90-days after transplant and the target is to follow ≥90% of the patients until this time. DGF and acute rejection will not be assessed in the feasibility trial, and instead this data will be analyzed in the full trial. Patient follow-up of clinical outcomes will occur at 1-year following KT in the full trial.

Study Significance: This pilot study seeks to assess whether we can recruit kidney transplant patients for an RCT and assess compliance to a surgical care bundle aiming to reduce the incidence of delayed graft function. Preserving graft function after transplant is critical to ensuring favourable outcomes. The primary objectives of this study will assess protocol adherence and outcome collection rates. The results of this pilot trial will serve as the rationale to conduct a large, randomized controlled trial with the use of the surgical care bundle to enhance the recovery of kidney transplant patients.

Being tested
Treatment bundle of care, Control Group
Keywords
Kidney Transplant, Surgical Bundle
Medical subject headings
Renal Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Treatment bundle of careOther

    The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure > 75 mmHg, identify and treat blood glucose > 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) < 70 g/L).

  • Control GroupOther

    Routine clinical care for kidney transplant patients

Study groups in NCT06724211
Study groupRoleWhat they receive
Control GroupActive comparatorRoutine clinical care for kidney transplant patients
Receives: Other: Control Group
Surgical bundleExperimentalThe surgical bundle will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure > 75 mmHg, identify and treat blood glucose > 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) < 70 g/L).
Receives: Other: Treatment bundle of care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recruitment rate

    Recruitment rate will be defined as the number of patients who are approached to participate in the study and who are randomized to either the treatment or routine clinical care group, as a percentage of the total number of eligible transplant patients.

    In order to complete a full multicenter trial in a reasonable time period (2-3 years), the number needed to recruit per week is at least 1 patient, but we will aim to recruit 2 patients per week.

    Measured: Baseline, pre-intervention/procedure/surgery

Secondary outcomes (2)
  1. Protocol adherence

    The aim is for ≥90% compliance with at least 3 of the 4 components of the perioperative bundle of care i.e. use of Plasmalyte for fluid management, maintenance of MAP > 75 mmHg from time of cross-clamp removal to 4-hours post KT, the initiation of an insulin infusion to maintain a serum blood sugar < 9 mmol/L and avoidance of RBC transfusion unless the Hb < 70 g/L or symptoms of oxygen insufficiency and Hb < 80 g/L.

    Measured: During the intervention/procedure/surgery AND immediately after the intervention/procedure/surgery

  2. Follow-up rate

    Patient follow-up will end at 90-days after transplant and the target is to follow ≥90% of the patients until this time. DGF and acute rejection will not be assessed in the feasibility trial, and instead this data will be analyzed in the full trial. Patient follow-up of clinical outcomes will occur at 1-year following KT in the full trial.

    Measured: 90-days after final patient recruited

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2024
  2. Study start15 Jan 2025 (estimated)
  3. Primary completionJan 2026 (estimated)
  4. Study completionApr 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Patients will be randomized to either the experimental group, which will consist of a treatment bundle of care, or to the control group, which will consist of routine clinical care for kidney transplant patients. The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure \> 75 mmHg, identify and treat blood glucose \> 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \< 70 g/L).
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06724211
Sponsor's protocol ID
24-5286
Acronym
PDF
Status last verified
Dec 2024
First submitted
26 Nov 2024
Last updated
9 Dec 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Sharing such detailed data can risk exposing sensitive personal information, even if anonymized. Additionally, there are often ethical and legal considerations that restrict the sharing of IPD to protect participants' rights and comply with regulations.

Publications

  • Sicova M, McGinn R, Emerson S, Perez P, Gonzalez R, Li Y, Famure O, Randall I, Mina DS, Santema M, Wijeysundera DN, Van Klei W, Kim SJ, McCluskey SA. Association of Intraoperative Hypotension With Delayed Graft Function Following Kidney Transplant: A Single Centre Retrospective Cohort Study. Clin Transplant. 2024 Oct;38(10):e70000. doi: 10.1111/ctr.70000.

    PubMed 39460628
  • Pascoe EM, Chadban SJ, Fahim MA, Hawley CM, Johnson DW, Collins MG; BEST-fluids Investigators and the Australasian Kidney Trials Network. Statistical analysis plan for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a randomised controlled trial of the effect of intravenous fluid therapy with balanced crystalloid versus saline on the incidence of delayed graft function in deceased donor kidney transplantation. Trials. 2022 Jan 18;23(1):52. doi: 10.1186/s13063-021-05989-w.

    PubMed 35042554

Questions about this trial

What is this clinical trial studying?

A study testing Treatment bundle of care in people with Kidney Transplant and Kidney Failure, run by University Health Network, Toronto at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 9 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Stuart Dr. McCluskey, MD, PhD, FRCPC (416-988-6233, Stuart.McCluskey@uhn.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recruitment rate (time frame: Baseline, pre-intervention/procedure/surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06724211, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in